Molecule Name |
DB09102
|
DrugBank Groups |
Approved
|
Cluster No |
856
|
Smiles |
O=C(OC)NC(C(=O)N6(C(C1(=NC=C(N1)C5(=CC=C(C4(=CC=C(C=3(NC(C2(N(C(=O)C(NC(=O)OC)C(C)C)CCC2))=NC=3))C=C4))C=C5)))CCC6))C(C)C
|
Download |
mol2, pdbqt
|
TPSA |
174,64
|
Non-H Atoms |
54
|
Non-C/H Atoms |
14
|
Metal-Atoms |
0
|
Electronegative Atoms |
14
|
Stereo Centers |
4
|
Rotatable Bonds |
13
|
Rings Closures |
6
|
Small Rings |
6
|
Aromatic Rings |
4
|
Aromatic Atoms |
22
|
sp3-Atoms |
20
|
Symmetric atoms |
30
|
cLogS |
-5,742
|
MW |
738,887
|
cLogP |
4,6938
|
HBA |
14
|
HBD |
4
|
Ro5 violations |
2
|
Druglikeness |
-7,4305
|
DrugScore |
0,137362717537871
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Blood-Brain Barrier |
BBB-
|
Human Intestinal Absorption |
HIA+
|
Caco-2 Permeability |
Caco2-
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Inhibitor
|
P-glycoprotein Inhibitor 2 |
Inhibitor
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Aqueous solubility |
-3,3859
|
Caco-2 Permeability 2 |
0,5374
|
Subcellular localization |
Mitochondria
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 2D6 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 1A2 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Inhibitor
|
CYP450 3A4 Inhibitor |
Inhibitor
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition 2 |
Inhibitor
|
AMES Toxicity |
Non AMES toxic
|
Carcinogens |
Non-carcinogens
|
Fish Toxicity |
High FHMT
|
Fish Toxicity (pLC50, mg/L) |
1,4434
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
0,5234
|
Honey Bee Toxicity |
Low HBT
|
Biodegradation |
Not ready biodegradable
|
Acute Oral Toxicity |
III
|
Rat Acute Toxicity (LD50, mol/kg) |
2,5746
|
Carcinogenicity (Three-class) |
Non-required
|